AXGN

NASDAQ Healthcare

Axogen, Inc. - Common Stock

Medical Devices

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

๐Ÿ“Š Market Data
Price$43.28
Volume759,225
Market Cap2.30B
Beta0.980
RSI (14-Day)81.7 Overbought
200-Day MA$25.82
50-Day MA$33.83
52-Week High$45.83
52-Week Low$9.22
Forward P/E56.82
Price / Book15.85
๐ŸŽฏ Investment Strategy Scores

AXGN scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 35/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 26/100โ–ฒ +3
High growth potential (high beta + oversold)
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 96/100โ€” 0
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (96/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿ”ช Falling Knife (1/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find AXGN in your text

Paste any article, transcript, or post โ€” the tool will extract AXGN and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.